

Lu Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3315208/publications.pdf>

Version: 2024-02-01

21
papers

5,629
citations

567281
15
h-index

677142
22
g-index

25
all docs

25
docs citations

25
times ranked

9291
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	12.6	1,872
2	Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 2016, 8, 346ra92.	12.4	1,036
3	Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017, 355, 1330-1334.	12.6	803
4	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	7.1	438
5	Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology, 2019, 5, 1710.	7.1	383
6	Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut, 2019, 68, 663-671.	12.1	234
7	Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, 2018, 10, .	12.4	178
8	Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer. JAMA Oncology, 2019, 5, 1118.	7.1	152
9	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	12.4	129
10	Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. ELife, 2018, 7, .	6.0	118
11	Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study. PLoS Medicine, 2021, 18, e1003620.	8.4	88
12	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	5.1	77
13	Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 423-429.	2.8	30
14	Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC).. Journal of Clinical Oncology, 2018, 36, 3516-3516.	1.6	19
15	The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. International Journal of Cancer, 2019, 145, 540-547.	5.1	15
16	Supervised mutational signatures for obesity and other tissue-specific etiological factors in cancer. ELife, 2021, 10, .	6.0	12
17	The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2017, 35, 3521-3521.	1.6	11
18	Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer.. Journal of Clinical Oncology, 2017, 35, 4101-4101.	1.6	9

#	ARTICLE	IF	CITATIONS
19	The potential of circulating tumor DNA (ctDNA) to reshape the design of clinical trials testing adjuvant therapy in patients with early stage cancers.. Journal of Clinical Oncology, 2016, 34, 3511-3511.	1.6	5
20	A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. Journal of Clinical Oncology, 2019, 37, 3518-3518.	1.6	5
21	Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, e16206-e16206.	1.6	4